ReviewDrugs1999
Drug therapy of postprandial hyperglycaemia.
Review in Drugs, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00065676 (Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics
Who cites it
30 citing papers in PubMed, 160 citations in OpenAlex.
- Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.BMJ open diabetes research & care · 2021Trial
- Sex-Specific Regulation of Glycemic Homeostasis by Theabrownin from Pu-erh Tea.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evaluation of modified benzaldehyde derivatives as dual α-glucosidase and α-amylase inhibitors: a viable alternative to acarbose.Food science and biotechnology · 2025Article
- A Treatment to Cure Diabetes Using Plant-Based Drug Discovery.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Activity-Based Protein Profiling of Retaining α-Amylases in Complex Biological Samples.Journal of the American Chemical Society · 2021Article
- New Fluorene Derivatives fromMolecules (Basel, Switzerland) · 2020Article
- Plant-Derived Bioactive Peptides: A Treatment to Cure Diabetes.International journal of peptide research and therapeutics · 2020Review
- Design and evaluation of chalconeimine derivatives as α-amylase inhibitors.Bioinformation · 2019Article
- Saponins and Flavonoids from Adzuki Bean (Frontiers in pharmacology · 2017Article
- Comparison of analytical techniques for the identification of bioactive compounds from natural products.Natural product reports · 2016Review
- Evaluation of a Standardized Extract fromEvidence-based complementary and alternative medicine : eCAM · 2016Article
- Magnetic Ligand Fishing as a Targeting Tool for HPLC-HRMS-SPE-NMR: α-Glucosidase Inhibitory Ligands and Alkylresorcinol Glycosides from Eugenia catharinae.Journal of natural products · 2015Article
- The amylase inhibitor montbretin A reveals a new glycosidase inhibition motif.Nature chemical biology · 2015Article
- Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.Nature · 2014Article
- Glucosidase inhibitory activity and antioxidant activity of flavonoid compound and triterpenoid compound from Agrimonia Pilosa Ledeb.BMC complementary and alternative medicine · 2014Article
- Preparation of the Branch Bark Ethanol Extract in Mulberry Morus alba, Its Antioxidation, and Antihyperglycemic Activity In Vivo.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Roles of chlorogenic Acid on regulating glucose and lipids metabolism: a review.Evidence-based complementary and alternative medicine : eCAM · 2013Review
- Article
- Antidiabetic Properties of Azardiracta indica and Bougainvillea spectabilis: In Vivo Studies in Murine Diabetes Model.Evidence-based complementary and alternative medicine : eCAM · 2011Article
- Enhanced modelling of the glucose–insulin system and its applications in insulin therapies.Journal of biological dynamics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is widely accepted that the most challenging goal in the management of patients with diabetes mellitus is to achieve blood glucose levels as close to normal as possible. In general, normalising postprandial blood glucose levels is more difficult than normalising fasting hyperglycaemia. In addition, some epidemiological studies suggest that postprandial hyperglycaemia (PPHG) or hyperinsulinaemia are independent risk factors for the development of macrovascular complications of diabetes mellitus. Recently, several drugs with differing pharmacodynamic profiles have been developed which target PPHG. These include insulin lispro, amylin analogues, alpha-glucosidase inhibitors and meglitinide analogues. Insulin lispro has a more rapid onset of action and shorter duration of efficacy compared with regular human insulin. In clinical trials, the use of insulin lispro was associated with improved control of PPHG and a reduced incidence of hypoglycaemic episodes. Repaglinide, a meglitinide analogue, is a short-acting insulinotropic agent which. when given before meals, stimulates endogenous insulin secretions and lowers postprandial hyperglycaemic excursions. Both insulin lispro and repaglinide are associated with postprandial hyperinsulinaemia. In contrast, amylin analogues reduce PPHG by slowing gastric emptying and delivery of nutrients to the absorbing surface of the gut. Alpha-Glucosidase inhibitors such as acarbose, miglitol and voglibose also reduce PPHG primarily by interfering with the carbohydrate-digesting enzymes and delaying glucose absorption. With the availability of agents which preferentially reduce postprandial blood glucose excursions, it is now possible to achieve glycaemic goals in a larger proportion of individuals with diabetes mellitus.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.